Peter Lommer Kristensen

Dr. Peter Lommer Kristensen

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
UPUlrik Pedersen-Bjergaard
Ulrik Pedersen-Bjergaard
PKPeter Lommer Kristensen
Peter Lommer Kristensen
HBHenning Beck-Nielsen
Henning Beck-Nielsen
KNKirsten Nørgaard
Kirsten Nørgaard
HPHans Perrild
Hans Perrild
LTLise Tarnow
Lise Tarnow

22 July 2014 in Diabetes
Verified
Journal Article
Closed access
MCMikkel Christensen
Mikkel Christensen
SCSalvatore Calanna
Salvatore Calanna
ASAlexander H. Sparre-Ulrich
Alexander H. Sparre-Ulrich
PKPeter Lommer Kristensen
Peter Lommer Kristensen
MRmette rosenkilde
mette rosenkilde
FKFilip Knop
Filip Knop
Glucose-dependent insulinotropic polypeptide (GIP) is glucagonotropic, and glucagon-like peptide-1 (GLP-1) is glucagonostatic. We studied the effects of GIP and GLP-1 on glucagon responses to insulin-induced hypoglycemia in patients with type 1 diabetes mellitus (T1DM). Ten male subjects with T1DM (C-peptide negative, age [mean ± SEM] 26 ± 1 years, BMI 24 ± 0.5 kg/m2, HbA1c 7.3 ± 0.2%) were studied in a randomized, double-blinded, crossover study, with 2-h intravenous administration of saline, GIP, or GLP-1. The first hour, plasma glucose was lowered by insulin infusion, and the second hour constituted a “recovery phase.” During the recovery phase, GIP infusions elicited larger glucagon responses (164 ± 50 [GIP] vs. 23 ± 25 [GLP-1] vs. 17 ± 46 [saline] min ⋅ pmol/L, P < 0.03) and endogenous glucose production was higher with GIP and lower with GLP-1 compared with saline (P < 0.02). On the GIP days, significantly less exogenous glucose was needed to keep plasma glucose above 2 mmol/L (155 ± 36 [GIP] vs. 232 ± 40 [GLP-1] vs. 212 ± 56 [saline] mg ⋅ kg−1, P < 0.05). Levels of insulin, cortisol, growth hormone, and noradrenaline, as well as hypoglycemic symptoms and cognitive function, were similar on all days. Our results suggest that during hypoglycemia in patients with T1DM, exogenous GIP increases glucagon responses during the recovery phase after hypoglycemia and reduces the need for glucose administration.

1 June 2011 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
KLK.H.W. Lange
K.H.W. Lange
TJT. Jansen
T. Jansen
SAS. Asghar
S. Asghar
PKPeter Lommer Kristensen
Peter Lommer Kristensen
MSM. Skjønnemand
M. Skjønnemand
PNP. Nørgaard
P. Nørgaard
Sympathetic block causes vasodilatation and increases in skin temperature (T(s)). However, the T(s) response after specific nerve blocking is unknown. In this study, we hypothesized that T(s) would increase after specific blocking of the nerve innervating that area. Forty-six patients undergoing hand surgery were included. We performed ultrasound-guided, specific nerve blocking of either the musculocutaneous, radial, ulnar, or median nerve in each patient and analysed T(s) in the forearm and hand at 2 min intervals in the following 22 min by the use of infrared thermography. Areas of interest corresponding to the cutaneous innervation area of each of the four nerves were defined and the mean T(s) in each area was analysed. Specific blocking of the ulnar and median nerves caused a substantial increase in mean (sd) T(s) in the areas innervated by these nerves [5.2 (3.2)°C and 5.1 (2.5)°C, respectively; both P<0.0001]. The increase was even larger at the fingertips. Median nerve blocking also increased T(s) in the area of the hand innervated by the radial nerve (P<0.0001). However, T(s) did not increase in any area after either musculocutaneous or radial nerve blocking. Specific blocking of the ulnar and median nerve causes substantial increases in T(s) in specific areas of the hand. In contrast, the specific blocking of the musculocutaneous or radial nerve does not increase T(s). Further studies are needed to clarify if these findings can be used to objectively evaluate brachial plexus block success.

1 January 2017 in Journal of Diabetes and its Complications
Verified
Journal Article
Closed access
ABAnne Margareta Banghoej
Anne Margareta Banghoej
HNHenriette Holst Nerild
Henriette Holst Nerild
PKPeter Lommer Kristensen
Peter Lommer Kristensen
UPUlrik Pedersen-Bjergaard
Ulrik Pedersen-Bjergaard
JFJesper Fleischer
Jesper Fleischer
LTLise Tarnow
Lise Tarnow

1 May 2013 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
CBChristiane Bay
Christiane Bay
PKPeter Lommer Kristensen
Peter Lommer Kristensen
UPUlrik Pedersen-Bjergaard
Ulrik Pedersen-Bjergaard
LTLise Tarnow
Lise Tarnow
BTBirger Thorsteinsson
Birger Thorsteinsson
Background: A reliable method to detect biochemical nocturnal hypoglycemia is highly needed, especially in patients with recurrent severe hypoglycemia. We evaluated reliability of nocturnal continuous glucose monitoring (CGM) in patients with type 1 diabetes at high risk of severe hypoglycemia. Patients and Methods: Seventy-two type 1 diabetes patients with recurrent severe hypoglycemia (two or more events within the last year) participated for 4 nights in blinded CGM recordings (Guardian® REAL-Time CGMS and Sof-Sensor®; Medtronic MiniMed, Northridge, CA). Blood was drawn hourly from 23:00 to 07:00 h for plasma glucose (PG) measurements (gold standard). Results: Valid data were obtained in 217 nights. The sensitivity of CGM was 65% (95% confidence interval, 53–77%) below 4 mmol/L, 40% (24–56%) below 3 mmol/L, and 17% (0–47%) below 2.2 mmol/L. PG and CGM readings correlated in the total measurement range (Spearman's ρ=0.82; P<0.001). In the normo- and hyperglycemic ranges CGM underestimated PG by 1.1 mmol/L (0.9–1.2 mmol/L) (P<0.001); in contrast, in the hypoglycemic range (PG<4 mmol/L) CGM overestimated PG levels by 1.0 mmol/L (P<0.001). The mean absolute relative differences in the hypo- (≤3.9 mmol/L), normo- (4–9.9 mmol/L), and hyperglycemic (≥10 mmol/L) ranges were 45% (37–53%), 23% (22–25%), and 20% (19–21%), respectively. Continuous glucose error grid analysis indicated a clinical accuracy of 56%, 99%, and 93% in the hypo-, normo-, and hyperglycemic ranges, respectively. Conclusions: The accuracy in the hypoglycemic range of nocturnal CGM data using Sof-Sensor is suboptimal in type 1 diabetes patients at high risk of severe hypoglycemia. To ensure clinical useful sensitivity in detection of nocturnal hypoglycemic episodes, an alarm threshold should not be lower than 4 mmol/L.

31 January 2022 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
CKCarina Kirstine Klarskov
Carina Kirstine Klarskov
NWNicole Avlund Windum
Nicole Avlund Windum
MOMikkel Thor Olsen
Mikkel Thor Olsen
ADArnold Matovu Dungu
Arnold Matovu Dungu
AJAndreas Kryger Jensen
Andreas Kryger Jensen
PKPeter Lommer Kristensen
Peter Lommer Kristensen
Objective: To investigate whether telemetric continuous glucose monitoring (CGM) in hospitalized and isolated patients with diabetes mellitus and coronavirus disease 2019 (COVID-19) is associated with better glycemic outcomes and fewer patient health care worker contacts compared to blood glucose monitoring by traditional point-of-care (POC) glucose testing and to investigate the user aspect of implementing a CGM-system in-hospital. Materials and Methods: A randomized controlled exploratory trial was performed on hospitalized and isolated patients with diabetes and COVID-19 from May 2020 until February 2021 at Nordsjællands Hospital, Denmark. Participants were randomized to nonblinded telemetric CGM (as the only glucose monitoring method) or traditional POC glucose testing + blinded CGM. The primary endpoint was time in range (TIR) based on CGM data in both groups. A questionnaire about the user aspect of the CGM system was answered by health care personnel (HCP). Results: We included 64 participants in the analysis, 31 in the CGM group and 33 in the POC glucose group. TIR median was 46% for the CGM group and 68% for the POC glucose group ( P = 0.368). The mean glucose value for the CGM group was 11.1 and 10.8 mmol/L in the POC glucose group ( P = 0.372). CGM was associated with fewer POC glucose measurements ( P < 0.001). Out of 30 HCPs, 28 preferred telemetric CGM over POC glucose testing. Conclusion: Remote glucose monitoring by CGM did not improve glycemic outcomes compared to traditional POC glucose testing, but was associated with fewer patient-personnel contacts, saving time for HCPs performing diabetes-related tasks. Most HCPs preferred CGM. The study is registered at http://www.clinicaltrials.gov (#NCT04430608).